---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-130017"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:41:47.551821+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharma gets FDA clearance for whole-body QRX003 study in Netherton Syndrome

## Summary
- FDA clearance for new Netherton Syndrome study of QRX003 applied to >80% BSA twice daily for 12 weeks in up to 8 patients.
- Prior studies used ~20% BSA; new whole-body design mimics real-world use to support potential regulatory approval.
- Study led by Dr. Amy Paller at Northwestern University; data to supplement QRX003 NDA package.
- Quoin is a clinical-stage specialty pharma focused on rare/orphan diseases; stock trades as QNRX.

## SEC filing metadata
- accession: 0001104659-24-130017
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465924130017/0001104659-24-130017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465924130017/tm2431545d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-130017
- JSON: https://secwatch.observer/filing/0001104659-24-130017.json
- Plain text: https://secwatch.observer/filing/0001104659-24-130017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.